What Is KPV Peptide?
KPV is a short peptide derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH). It is classified as a tripeptide and is identified chemically as L-lysyl-L-prolyl-L-valine.
The name KPV refers to the three amino-acid residues lysine, proline, and valine that make up this peptide. In published research, KPV has been examined as an isolated α-MSH-derived peptide rather than as the complete α-MSH molecule.
Research Overview Table
Chemical and Molecular Characteristics
KPV occurs as a short peptide with the chemical structure H-Lys-Pro-Val-OH. The free-acid form differs from amidated Lys-Pro-Val derivatives, which represent chemically distinct peptide forms.
A published stability study found that KPV undergoes degradation under acidic, alkaline, and oxidative stress conditions. The study identified Lys-Pro diketopiperazine as the major degradation product under the tested conditions.
Certificates:
Mechanism of Action Under Investigation
Published studies have not established a single receptor target for KPV. In intestinal epithelial and immune cells, researchers found that PepT1 transports KPV into cells. The study linked KPV uptake with changes in NF-κB and MAPK signaling and measured these effects using reporter assays, Western blotting, RT-PCR, and ELISA.
In human bronchial epithelial cells, researchers found that KPV entered the nucleus, stabilized IκBα, and reduced nuclear translocation of p65/RelA. Competition experiments indicated that KPV interacted with the importin-α3 binding region of p65/RelA.
Other experiments found that KPV did not increase cAMP and that its activity was not blocked by an MC3/4 receptor antagonist, providing evidence against a conventional melanocortin-receptor mechanism in those models.
Evidence therefore describes PepT1-mediated uptake and intracellular NF-κB-related signaling, rather than one confirmed receptor-mediated mechanism. The exact molecular mechanism remains unresolved.
Scientific Research Context
KPV appears in published research as an α-MSH-derived peptide investigated mainly in cell-based and animal studies. Researchers have examined KPV in cultured epithelial and immune cells and in several experimental animal models. The literature includes early cellular studies followed by investigations in mouse models of intestinal inflammation and other preclinical systems. Overall, the evidence base remains predominantly preclinical. with research focused on laboratory and animal models rather than an established body of human clinical evidence.
KPV Biology and Biological Pathways
Primary Biological Function
KPV is studied in relation to epithelial, immune, and inflammatory biology. Researchers have examined its effects in intestinal epithelial cells, immune cells, keratinocytes and airway epithelial cells. These systems provide models for studying how short α-MSH-derived peptides interact with cellular processes involved in tissue homeostasis and inflammatory responses.
Relevant Metabolic or Signaling Pathways
KPV research has examined NF-κB and MAPK signaling in cellular models, including keratinocytes. One study also reported KPV-associated changes in intracellular calcium signaling in human keratinocytes. More recent studies have investigated KPV in ROS-related AKT/mTORC1 and PPARγ signaling in adipocyte and hepatic cell models. These findings expand the published research into metabolic signaling, but they come from recent preclinical studies and should not be treated as established pathways for KPV across biological systems.
Tissue-Specific Biology
Research on KPV spans intestinal, airway, skin, and adipose tissues. Intestinal studies have examined epithelial and immune cells, while airway research has investigated human bronchial epithelial cells. Skin research has examined human keratinocytes. More recent research has extended KPV studies to adipocytes and adipose tissue adding a metabolic tissue context to the existing literature.
Experimental Biomarkers
Published KPV studies have measured NF-κB activity, IL-8, eotaxin, and matrix metalloproteinase-9 activity in airway epithelial cells, along with pro-inflammatory cytokine expression in intestinal studies. More recent KPV research has measured reactive oxygen species, intracellular triglycerides, PPARγ, fatty acid synthase, AKT/mTORC1 signaling, and ERK phosphorylation in adipocyte and hepatic cell studies. These markers provide measurable molecular and cellular readouts for the biological processes examined in each study.
Laboratory Investigation Methods
Published KPV studies use cell culture, animal models, reporter assays, Western blotting, real-time RT-PCR, ELISA, radiolabeled uptake assays and histological analysis. Researchers have also used fluorescence imaging to examine KPV uptake and intracellular distribution. These methods allow researchers to measure molecular and cellular responses in defined experimental systems.
Experimental Models Used in Published Research
Published KPV research includes human cell-based systems and mouse models, with much of the established experimental work focused on intestinal biology. The cellular systems provide controlled settings for studying KPV in specific human cell types, while animal models provide greater biological complexity. Each model has limitations, particularly differences between isolated cells, experimental disease models, and normal human physiology.
Intestinal Epithelial Cell Models
Caco2-BBE and HT29-Cl.19A are human intestinal epithelial cell lines used in KPV research. Caco2-BBE provides an hPepT1-expressing intestinal system, while HT29-Cl.19A provides a system with little or no basal hPepT1 expression. Their main limitation is that cell lines cannot reproduce the complexity of intact intestinal tissue.
Human T-Cell Model
Jurkat T cells were included in the primary KPV study as a human immune-cell system alongside intestinal epithelial cells. The study used them to examine KPV in an immune-cell context and assessed cellular responses with molecular assays. Because Jurkat cells are an immortalized cell line, they do not fully represent primary human T-cell biology.
Chemically Induced Colitis Models
DSS- and TNBS-induced colitis in C57BL/6 mice provides two experimental models of intestinal inflammation. Researchers use these models to examine KPV within an intact gastrointestinal system. Their limitations include species differences and the fact that chemically induced inflammation does not reproduce every feature of human intestinal disease.
PepT1-Modified Mouse Models
PepT1-knockout, wild-type, and PepT1-transgenic mice have been used to study KPV in relation to intestinal PepT1 biology. These genetically defined models allow comparisons between different PepT1 states. Their main limitation is that genetically altered animals may not reflect the range of PepT1 expression and regulation found in humans.
Apc<sup>Min/+</sup> Mouse Model
Apc<sup>Min/+</sup> mice provide a genetic model of intestinal adenoma formation. This model represents a different experimental setting from chemically induced colitis and allows researchers to study KPV within genetically driven intestinal disease. Its limitation is that this specific APC mutation does not represent the full biological diversity of human colorectal disease.
KPV Published Research
Intestinal Inflammation
KPV research has focused substantially on intestinal inflammation. Studies have examined KPV in intestinal epithelial cells, human T cells, and mouse models of colitis. Researchers investigated inflammatory signaling, cytokine expression, intestinal tissue changes, and KPV uptake through PepT1. Later work extended this research to colitis-associated cancer using PepT1-transgenic, wild-type, and PepT1-knockout mice.
PepT1-Related Research
Researchers have investigated PepT1-mediated KPV uptake in intestinal cells. The original study used radiolabeled KPV and competition experiments to examine PepT1-mediated cellular uptake. Later work compared PepT1-transgenic, wild-type, and PepT1-knockout mice to investigate KPV in PepT1-dependent intestinal research.
Airway Epithelial Research
KPV has been investigated in immortalized human bronchial epithelial cells (16HBE14o−) exposed to TNF-α and respiratory syncytial virus. Researchers examined NF-κB activity and measured IL-8, eotaxin, and MMP-9 responses. The study also investigated IκBα stability and the nuclear translocation of p65/RelA to characterize how KPV affected NF-κB signaling under the experimental conditions.
Keratinocyte Research
Published research has examined KPV in HaCaT and normal human keratinocytes alongside α-MSH, KP-D-V, and ACTH peptides. The study measured intracellular cAMP and calcium responses. It found no increase in cAMP in either keratinocyte system. Rapid calcium responses occurred with KPV, but in HaCaT cells these responses were observed in the presence of PIA.
KPV-Based Delivery Research
Researchers have also investigated KPV as a component of targeted peptide-delivery systems. Studies have incorporated KPV into nanoparticles, peptide conjugates, and other delivery platforms and examined peptide stability, intestinal delivery, tissue distribution, and responses in experimental disease models. This work evaluates KPV-containing delivery systems rather than KPV alone.
Recent Metabolic Research
KPV has recently been studied in adipocyte and hepatic lipid biology. One study examined KPV during adipocyte differentiation in 3T3-L1 preadipocytes and a high-fat-diet mouse model. Another used oleic-acid-treated HepG2 cells to examine KPV in relation to hepatic lipid accumulation and oxidative stress.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The available KPV evidence is predominantly preclinical. The published literature does not provide a substantial body of clinical research in humans. This limits the strength of conclusions that can be drawn beyond the experimental settings in which KPV has been studied.
Human Clinical Evidence
Human clinical evidence is currently limited. FDA reported that it had not identified clinical studies or human exposure data for KPV by any route of administration. Therefore, the literature does not establish human clinical responses or provide direct clinical evidence for KPV.
Species Differences
Animal findings may not translate directly to human biology. KPV research includes animal studies but the published literature does not establish that responses observed in those animals will occur in humans. The lack of identified human exposure data also prevents direct comparison between KPV responses in animals and humans.
Study Design Limitations
The KPV studies use different experimental conditions, concentrations, treatment protocols and outcome measures. This variation makes direct comparison difficult. Findings from one study therefore do not necessarily apply to another experimental setting, particularly when researchers use different biological systems or delivery approaches.
Independent Replication
The KPV literature does not establish broad independent replication across its different research areas. Some findings have been reported in more than one study but the available literature remains relatively small and heterogeneous. Further studies by independent research groups would help determine how consistently these findings can be reproduced.
Long-Term Evidence
Long-term human evidence is lacking. FDA reported no identified human exposure data for KPV and no clinical studies assessing its use in humans. Consequently, the available literature does not establish how KPV behaves or what effects may occur with prolonged exposure in humans.
Analytical Documentation
HPLC has been used specifically to analyze KPV. A published stability indicating method separated KPV from degradation products and other components in aqueous solutions and skin homogenates.
LC-MS can complement chromatographic analysis. In the KPV study, mass spectrometry identified a major degradation product formed under stress conditions.
NMR can provide structural information for peptide characterization when appropriate, but I did not identify a KPV-specific NMR study in the literature reviewed here.
A Certificate of Analysis records quality-control results for a specific preparation, including identity, purity, and analytical testing. Analytical documentation helps verify what a laboratory preparation contains. It verifies identity and quality not biological performance.
Storage and Laboratory Handling
KPV should remain sealed and stored at 2–8°C. According to the product-specific Certificate of Analysis. Laboratory personnel should handle the material using appropriate laboratory procedures and take steps to prevent contamination during storage and handling. Keep the material protected from conditions that could affect its quality and follow the storage requirements documented for the specific batch.
KPV is intended for laboratory research use only. Handling should be limited to qualified personnel working in an appropriate laboratory environment.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.